Navigation Links
ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
Date:9/27/2010

scores were recorded prior to the first treatment with REMURA and were compared to scores at Day 14, Day 42 and Day 52.

Authors of the posters were Simon P. Chandler, Ph.D., James A. Gow, M.D. and Timothy R. McNamara, Pharm.D. of ISTA Pharmaceuticals, Inc., Irvine, CA, USA; Sheri L. Rowen, M.D., of the Mercy Medical Eye and Cosmetic Surgery Center, Baltimore, MD, USA; and Neal A. Sher, M.D., F.A.C.S., Partner, Eye Care Associates, Minneapolis, MN, USA.

ISTA recently announced the Company has initiated its REMURA Phase 3 clinical study program.  Two Phase 3 studies to evaluate the efficacy and safety of REMURA are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA), and two remaining Phase 3 safety studies are the subject of additional SPAs currently under review by the FDA.  ISTA anticipates starting the remaining safety studies later this year and reporting results for the first two Phase 3 efficacy and safety studies in the middle of 2011.

ABOUT DRY EYE DISEASE

Dry eye occurs when there is an imbalance of tears that provides moisture and lubrication to the eye, which can result in pain, itching, redness, blurry vision, light sensitivity and/or a gritty sensation or feeling of sand in the eye.  Causes for dry eye include environmental conditions such as air conditioning, smoke and dust, aging and menopause, side-effects from antihistamines and birth control pills, Sjogren's syndrome, rheumatoid arthritis and structural problems with the eye lid's ability to close. Left untreated, dry eye can lead to abrasions on the surface of the eye and damage to the cornea. Current treatments include artificial tears and ointments, topical steroids, a topical immunomodulator that is the only approved prescription eye drop treatment, and punctal occlusion (closing or plugging of tear drains).  

ABOUT REMURA AND BROMFENAC OPHTHALMIC SOLUTION'/>"/>

SOURCE ISTA Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
2. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
3. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
6. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
7. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
8. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. ... cancers, today announced that Linda Powers , NW Bio CEO, ... vaccine platform for solid tumor cancers and the Company,s multiple ...   , , , DATE: , , , ... , , , 12:15 PM EDT , , , ...
(Date:5/6/2015)... May 06, 2015 Park Systems ... NX-Hivac, the only high vacuum AFM system in the ... failure analysis semiconductor manufacturing. Park NX-Hivac is ideal for ... analysis solutions in highly doped semiconductor processing where more ... , The high vacuum scanning spreading resistance microscopy (SSRM) ...
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine company ... grown under simulated embryonic conditions, will present new ... melanoma during the 2015 Society of Investigative Dermatology ... in Atlanta, GA. , Histogen has previously shown ... with anti-oncologic properties, with potential benefit in the ...
(Date:5/6/2015)... 06, 2015 The Remedy Group ... strategy for the specialty pharmacy industry, will be exhibiting, ... Armada Specialty Pharmacy Summit. The Summit will be held ... Vegas and is the largest annual gathering for the ... attendance, from pharmacy providers, pharma/biotech manufacturers, and payers, to ...
Breaking Biology Technology:NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2
... Corp. (TSX: HBP / Frankfurt: WKN 918864), ... Corp.,announces that at the Company,s Annual General Meeting ... the resolutions presented by,management, appointing KPMG LLP as ... Kay, Slawomir Majewski, and Gordon Lickrish as,directors, and ...
... Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... novel anti-infective products, today,announced that it has closed ... warrants, resulting in the receipt of $21 million ... the proceeds from the financing to support,the manufacture ...
... Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... bio-enhanced feed products sold during the fourth,quarter of ... and increased,25% over the same period in the ... ("Kiwa Tianjin") is a joint-venture of Kiwa,and Tianjin ...
Cached Biology Technology:Helix BioPharma shareholders vote in favour of management 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... -- Rice University scientists have unveiled a revolutionary new ... into steam. The new "solar steam" method from Rice,s ... even produce steam from icy cold water. Details ... in ACS Nano . The technology has an ...
... after Hurricane Sandy hit, NJIT Professor Michel Boufadel was awarded ... of the storm on the New Jersey shoreline. The ... a team of eight researchers to the beaches of Raritan ... students is still fanning out over the shoreline and ...
... getting, when they select females for mating, according to a ... Wisconsin-Milwaukee in the US. His work, which is one of ... mating behaviors in a nocturnal anuran (frog or toad), is ... . Animals display a number of courtship behaviors and ...
Cached Biology News:Rice unveils super-efficient solar-energy technology 2Rice unveils super-efficient solar-energy technology 3NJIT civil engineer receives NSF grant to study storm's impact on Jersey Shore 2Vision stimulates courtship calls in the grey tree frog 2
... Cultures (ECACC) in conjunction with the Univeristy ... England, Bristol, UK, have produced standardised cell ... oestrogen and progresterone receptor assays. The slides ... fixed, breast cancer cell lines; MDA-MD-361, T47D, ...
kismet (dK-20)...
... potent TURBO DNase (patent pending) in the TURBO ... DNA removal capabilities. TURBO DNase is a recombinant, ... more efficient than wild type DNase I in ... DNase binds DNA substrates 6-fold more tightly than ...
...
Biology Products: